ROSUVASTATIN CALCIUM tablet United States - English - NLM (National Library of Medicine)

rosuvastatin calcium tablet

avkare, inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 5 mg

FAMCICLOVIR tablet, film coated United States - English - NLM (National Library of Medicine)

famciclovir tablet, film coated

avkare, inc. - famciclovir (unii: qic03ani02) (penciclovir - unii:359hue8fjc) - famciclovir 125 mg - herpes labialis (cold sores): famciclovir tablets are indicated for the treatment of recurrent herpes labialis. genital herpes: recurrent episodes: famciclovir tablets are indicated for the treatment of recurrent episodes of genital herpes. the efficacy of famciclovir tablets when initiated more than 6 hours after onset of symptoms or lesions has not been established. suppressive therapy: famciclovir tablets are indicated for chronic suppressive therapy of recurrent episodes of genital herpes. the efficacy and safety of famciclovir tablets for the suppression of recurrent genital herpes beyond 1 year have not been established. herpes zoster (shingles): famciclovir tablets are indicated for the treatment of herpes zoster. the efficacy of famciclovir tablets when initiated more than 72 hours after onset of rash has not been established. recurrent orolabial or genital herpes: famciclovir tablets are indicated for the treatment of recurrent episodes of orolabial or genital herpes in hiv-infected adults. the

DARIFENACIN HYDROBROMIDE EXTENDED-RELEASE- darifenacin hydrobromide tablet, extended release United States - English - NLM (National Library of Medicine)

darifenacin hydrobromide extended-release- darifenacin hydrobromide tablet, extended release

avkare, inc. - darifenacin hydrobromide (unii: cr02eyq8gv) (darifenacin - unii:apg9819vlm) - darifenacin 7.5 mg - darifenacin hydrobromide extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. darifenacin hydrobromide extended-release tablets are contraindicated in patients with, or at risk for, the following conditions: - urinary retention - gastric retention, or - uncontrolled narrow-angle glaucoma. pregnancy category c there are no studies of darifenacin in pregnant women. darifenacin was not teratogenic in rats and rabbits at plasma exposures of free drug (via auc) up to 59 times and 28 times, respectively (doses up to 50 and 30 mg/kg/day, respectively) the maximum recommended human dose [mrhd] of 15 mg. at approximately 59 times the mrhd in rats, there was a delay in the ossification of the sacral and caudal vertebrae which was not observed at approximately 13 times the auc. dystocia was observed in dams at approximately 17 times the auc (10 mg/kg/day). slight developmental delays were observed in pups

MEMANTINE HYDROCHLORIDE- memantine tablet, film coated United States - English - NLM (National Library of Medicine)

memantine hydrochloride- memantine tablet, film coated

avkare, inc. - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 5 mg - memantine hydrochloride (hcl) tablets, usp are indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hcl tablets, usp are contraindicated in patients with known hypersensitivity to memantine hydrochloride, usp or to any excipients used in the formulation. pregnancy category b there are no adequate and well-controlled studies of memantine in pregnant women. memantine hcl should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [mrhd] on a mg/m 2 basis). slight maternal toxicity, decreased pup weights and an increased incidence of non-ossified cervical vertebrae were seen at an oral dose of 18 mg/kg/day in a study in which rats were given oral memantine be

VORICONAZOLE tablet film coated United States - English - NLM (National Library of Medicine)

voriconazole tablet film coated

avkare, inc. - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 200 mg

Moexipril Hydrochloride and Hydrochlorothiazide Tablets USP  
 
 
 Rx only United States - English - NLM (National Library of Medicine)

moexipril hydrochloride and hydrochlorothiazide tablets usp rx only

avkare, inc. - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride and hydrochlorothiazide tablets usp are indicated for treatment of patients with hypertension. this fixed combination is not indicated for the initial therapy of hypertension (see dosage and administration). in using moexipril hydrochloride and hydrochlorothiazide tablets usp, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride and hydrochlorothiazide tablets usp do not have a similar risk (see warnings , neutropenia/agranulocytosis ). in addition, ace inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients (see warnings , angioedema ). moexipril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitiv

PHENAZOPYRIDINE HYDROCHLORIDE tablet United States - English - NLM (National Library of Medicine)

phenazopyridine hydrochloride tablet

avkare, inc. - phenazopyridine hydrochloride (unii: 0ewg668w17) (phenazopyridine - unii:k2j09emj52) - phenazopyridine hydrochloride 100 mg - phenazopyridine hcl is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. the use of phenazopyridine for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. the drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. phenazopyridine is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. treatment of a urinary tract infection with phenazopyridine should not exceed 2 days. there is no evidence that the combined administration of phenazopyridine and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (see dosage and administration.) in p

SILDENAFIL tablet film coated United States - English - NLM (National Library of Medicine)

sildenafil tablet film coated

avkare, inc. - sildenafil citrate (unii: bw9b0ze037) (sildenafil - unii:3m7ob98y7h) - sildenafil 20 mg

METFORMIN HYDROCHLORIDE tablet United States - English - NLM (National Library of Medicine)

metformin hydrochloride tablet

avkare, inc. - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 500 mg - metformin hcl tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. metformin hcl, usp is contraindicated in patients with: 1. renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dl [males], ≥1.4 mg/dl [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings and precautions). 2. known hypersensitivity to metformin hcl, usp. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. metformin hcl, usp should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. (see also p

ATENOLOL- atenolol tablet United States - English - NLM (National Library of Medicine)

atenolol- atenolol tablet

avkare, inc. - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 25 mg - atenolol tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with diffe